Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Croma-Pharma

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hyaluronic Acid

            Therapeutic Area: Dermatology Product Name: Hyaluronic Acid Filler Princess

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: China National Biotech Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 15, 2020

            Details:

            The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin product Heng Li®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Botulinum toxin type A

            Therapeutic Area: Dermatology Product Name: BoNT/A-DP

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            Details:

            Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.